Acute acute bacterial skin and skin structure infections

Also known as: Acute Bacterial Skin and Skin Structure Infection / Acute Bacterial Skin and Skin Structure Infections

DrugDrug NameDrug Description
DB12455OmadacyclineOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.
DB09042Tedizolid phosphateTedizolid Phosphate is an oxazolidinone-class antibiotic prodrug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of several Gram-positive bacteria. Following administration via oral or intravenous route, tedizolid phosphate prodrug is converted by plasma phosphatases to its active moiety, [tedizolid]. The active metabolite of tedizolid binds to the 50S bacterial ribosomal subunit, inhibiting protein synthesis and causing its bacteriostatic effects. Tedizolid is an effective and potent alternative to linezolid for the treatment of patients with Gram-positive ABSSSI due to MRSA or MSSA. Increased potency allows for once daily dosing with reduced total dosages, improving the side effect profile of this drug. Of note, the minimum inhibitory concentrations of tedizolid appear to be largely unaffected by the chloramphenicol-florfenicol resistance (cfr) gene, which has been implicated in a number of published linezolid-resistant organism outbreaks.
DrugDrug NamePhaseStatusCount
DB04911Oritavancin1Not Yet Recruiting1
DB00601Linezolid2Completed1
DB14733Ceftobiprole medocaril3Recruiting1
DB00601Linezolid3Completed1
DB00601Linezolid3Recruiting1
DB09042Tedizolid phosphate3Recruiting1
DB06590Ceftaroline fosamil4Terminated1
DB06219Dalbavancin4Completed2
DB00080Daptomycin4Terminated1
DB00601Linezolid4Terminated1
DB04911Oritavancin4Completed1
DB00512Vancomycin4Terminated1